A Phase 1, Non‑Randomized, Open‑Label, Single‑Dose, Single Period Study With Non‑Pharmacologically Active Dose Of PF‑06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects
Latest Information Update: 23 Dec 2014
At a glance
- Drugs PF 6427878 (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Dec 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Planned End Date changed from 30 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 16 Sep 2014 New trial record